- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT05225194
Long-term Impact of COVID-19 Among COVID-19 Patients With Acute Respiratory Distress Syndrome in Brazil
Prospective Study for the Assessment of Long-term Impact of COVID-19 Among COVID-19 Patients With Acute Respiratory Distress Syndrome in Brazil
The present multicenter prospective observational study aims to assess the long-term effects of COVID-19 on patients with Acute Respiratory Distress Syndrome (ARDS).
This is a hybrid design study with components of cohort and case-control designs. Survivors of hospitalization due to ARDS caused by SARS-CoV-2, survivors of hospitalization due to ARDS caused by other etiologies not associated with SARS-CoV-2, and family controls without history of COVID-19 or hospitalization will be followed up for a period of 6 months.
Tutkimuksen yleiskatsaus
Opintotyyppi
Ilmoittautuminen (Odotettu)
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Geraldine Trott, PhD
- Puhelinnumero: +5551994407117
- Sähköposti: geraldine.trott@hmv.org.br
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Näytteenottomenetelmä
Tutkimusväestö
Kuvaus
COHORT OF SURVIVORS OF ARDS CAUSED BY COVID-19
Inclusion Criteria:
- Age ≥18 years;
- Hospitalization due to COVID-19;
- Positive polymerase chain reaction (PCR) test for SARS-CoV-2;
- Diagnosis of ARDS during hospitalization according to the Berlin definition;
- Expected to survive and be discharged directly home from the hospital.
Exclusion Criteria:
- Severe comorbidity with life expectancy less than 3 months;
- Unavailability to attend the study follow-up appointment;
- Death during hospitalization;
- Absence of proxy for patients with communication difficulties;
- Refusal or withdrawal of agreement to participate.
COHORT OF SURVIVORS OF ARDS CAUSED BY OTHER ETIOLOGIES NOT ASSOCIATED WITH COVID-19
Inclusion Criteria:
- Age ≥18 years;
- Hospitalization;
- Diagnosis of ARDS during hospitalization according to the Berlin definition;
- Expected to survive and be discharged directly home from the hospital.
Exclusion Criteria:
- Severe comorbidity with life expectancy less than 3 months;
- Unavailability to attend the study follow-up appointment;
- Death during hospitalization;
- History of SARS-CoV-2 infection within the last 12 months;
- Absence of proxy for patients with communication difficulties;
- Refusal or withdrawal of agreement to participate.
FAMILY CONTROLS
Inclusion Criteria:
- Age ≥18 years;
- Family member of a enrolled participant (either from the COVID-19 ARDS cohort or from the non-COVID-19 ARDS cohort)
Exclusion Criteria:
- Severe comorbidity with life expectancy less than 3 months;
- Unavailability to attend the study follow-up appointment;
- History of SARS-CoV-2 infection within the last 12 months;
- History of non-elective hospitalization due to medical condition within the last 12 months;
- Refusal or withdrawal of agreement to participate.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
Kohortit ja interventiot
Ryhmä/Kohortti |
Interventio / Hoito |
---|---|
COVID-19 ARDS survivors
Survivors of hospitalization due to ARDS caused by SAS-CoV-2.
|
SARS-CoV-2 infection
Acute respiratory distress syndrome
|
Non-COVID-19 ARDS survivors
Survivors of hospitalization due to ARDS caused by other etiologies than SARS-CoV-2.
|
Acute respiratory distress syndrome
|
Family controls
Family controls of participants with ARDS (either due to COVID-19 or other etiologies) without history of COVID-19 or hospitalization in the last 12 months.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Diffusion capacity for carbon monoxide
Aikaikkuna: The outcome will be assessed 6 months after enrollment
|
Proportion of participants with diffusion capacity for carbon monoxide < 80% of predicted
|
The outcome will be assessed 6 months after enrollment
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Physical functional status
Aikaikkuna: The outcome will be assessed at 3 and 6 months after enrollment
|
Physical functional status as assessed by the modified Barthel index (score ranges from 0 to 100; higher scores indicate less functional dependence)
|
The outcome will be assessed at 3 and 6 months after enrollment
|
Instrumental Activities of Daily Living
Aikaikkuna: The outcome will be assessed at 3 and 6 months after enrollment
|
The outcome will be assessed using the Lawton & Brody Instrumental Activities of Daily Living Scale (the score ranges from 0 to 8, with higher scores indicating less dependence)
|
The outcome will be assessed at 3 and 6 months after enrollment
|
Muscular function and strength
Aikaikkuna: The outcome will be assessed at 3 and 6 months after enrollment
|
Muscular function and strength as assessed by Strength, assistance with walking, rising from a chair, climbing stairs, and falls (SARC-F) questionnaire.
Scale scores range from 0 (best) to 10 (worst)
|
The outcome will be assessed at 3 and 6 months after enrollment
|
Score of dyspnea
Aikaikkuna: The outcome will be assessed at 3 and 6 months after enrollment
|
The outcome will be assessed using the modified medical research council dyspnea scale.
Scores ranges from 0 to 4, with higher scores indicating worse symptoms.
|
The outcome will be assessed at 3 and 6 months after enrollment
|
Utility score of health related quality of life
Aikaikkuna: The outcome will be assessed at 3 and 6 months after enrollment
|
The outcome will be assessed using the Brazilian version of the Euroqol-5D-3L (EQ-5D3L) questionnaire.
The utility score derived from the EQ5D-3L ranges from 0 (death) to 1 (perfect health).
|
The outcome will be assessed at 3 and 6 months after enrollment
|
Radiologic patterns of intersticial lung disease
Aikaikkuna: The outcome will be assessed at 6 months after enrollment
|
Radiologic patterns of intersticial lung disease as assessed by high resolution computed tomography chest scan.
|
The outcome will be assessed at 6 months after enrollment
|
Radiologic patterns of myocarditis sequalae
Aikaikkuna: The outcome will be assessed at 6 months after enrollment
|
Radiologic patterns of myocarditis sequalae as assessed by cardiac magnetic resonance imaging
|
The outcome will be assessed at 6 months after enrollment
|
Radiologic patterns of sarcopenia
Aikaikkuna: The outcome will be assessed at 6 months after enrollment
|
Radiologic patterns of sarcopenia as assessed by high resolution computed tomography chest scan.
|
The outcome will be assessed at 6 months after enrollment
|
Incidence of major cardiovascular events
Aikaikkuna: The outcome will be assessed at 3 and 6 months after enrollment
|
Incidence of major cardiovascular events (composite endpoint of non-fatal stroke, non-fatal acute myocardial infarction, or cardiovascular death)
|
The outcome will be assessed at 3 and 6 months after enrollment
|
Incidence of thromboembolic events
Aikaikkuna: The outcome will be assessed at 3 and 6 months after enrollment
|
Incidence of thromboembolic events (composite endpoint of pulmonary embolism and deep venous thrombosis)
|
The outcome will be assessed at 3 and 6 months after enrollment
|
Incidence of all-cause mortality
Aikaikkuna: The outcome will be assessed at 3 and 6 months after enrollment
|
Incidence of all-cause mortality
|
The outcome will be assessed at 3 and 6 months after enrollment
|
Percentage of predicted peak oxygen consumption
Aikaikkuna: The outcome will be assessed at 6 months after enrollment
|
Percentage of predicted peak oxygen consumption as assessed by treadmill cardiopulmonary exercise cardiopulmonary exercise
|
The outcome will be assessed at 6 months after enrollment
|
Peak oxygen consumption
Aikaikkuna: The outcome will be assessed at 6 months after enrollment
|
Peak oxygen as assessed by treadmill cardiopulmonary exercise
|
The outcome will be assessed at 6 months after enrollment
|
Peak oxygen pulse
Aikaikkuna: The outcome will be assessed at 6 months after enrollment
|
Peak oxygen pulse as assessed by treadmill cardiopulmonary exercise
|
The outcome will be assessed at 6 months after enrollment
|
Oxygen uptake efficiency slope
Aikaikkuna: The outcome will be assessed at 6 months after enrollment
|
Oxygen uptake efficiency slope as assessed by treadmill cardiopulmonary exercise
|
The outcome will be assessed at 6 months after enrollment
|
Minute ventilation/carbon dioxide production slope ratio
Aikaikkuna: The outcome will be assessed at 6 months after enrollment
|
Minute ventilation/carbon dioxide production slope as assessed by treadmill cardiopulmonary exercise
|
The outcome will be assessed at 6 months after enrollment
|
Forced vital capacity
Aikaikkuna: The outcome will be assessed at 6 months after enrollment
|
Forced expiratory capacity as assessed by spirometry
|
The outcome will be assessed at 6 months after enrollment
|
Forced expiratory volume in one second
Aikaikkuna: The outcome will be assessed at 6 months after enrollment
|
Forced expiratory volume in one second as assessed by spirometry
|
The outcome will be assessed at 6 months after enrollment
|
Forced expiratory volume in one second/ Forced vital capacity ratio
Aikaikkuna: The outcome will be assessed at 6 months after enrollment
|
Forced expiratory volume in one second/ Forced vital capacity ratio as assessed by spirometry
|
The outcome will be assessed at 6 months after enrollment
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Päätutkija: Regis G Rosa, MD, PhD, Hospital Moinhos de Vento
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Odotettu)
Ensisijainen valmistuminen (Odotettu)
Opintojen valmistuminen (Odotettu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Koronavirusinfektiot
- Coronaviridae-infektiot
- Nidovirales-infektiot
- RNA-virusinfektiot
- Virussairaudet
- Infektiot
- Hengitysteiden infektiot
- Hengityselinten sairaudet
- Hengityshäiriöt
- Keuhkokuume, virus
- Keuhkokuume
- Keuhkosairaudet
- Vauva, vastasyntynyt, sairaudet
- Keuhkovaurio
- Vauva, Keskoset, Sairaudet
- COVID-19
- Hengitysvaikeusoireyhtymä
- Hengitysvaikeusoireyhtymä, vastasyntynyt
- Akuutti keuhkovaurio
Muut tutkimustunnusnumerot
- Pos-COVID Brasil 3
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset COVID-19
-
Yang I. PachankisAktiivinen, ei rekrytointiCOVID-19 hengitystieinfektio | COVID-19 stressisyndrooma | COVID-19-rokotteen haittavaikutus | COVID-19:ään liittyvä tromboembolia | COVID-19:n jälkeinen tehohoidon oireyhtymä | COVID-19:ään liittyvä aivohalvausKiina
-
Indonesia UniversityRekrytointiCOVID-19 jälkeinen oireyhtymä | Pitkä COVID | COVID-19 jälkeinen tila | COVID-jälkeinen oireyhtymä | Pitkä COVID-19Indonesia
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRekrytointiCovid-19-pandemia | Covid-19-rokotteet | COVID-19 virustautiIndonesia
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico ja muut yhteistyökumppanitValmisCOVID-19:n akuutit jälkiseuraukset | COVID-19 jälkeinen tila | Pitkä COVID | Krooninen COVID-19-oireyhtymäItalia
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRekrytointiCOVID-19-keuhkokuume | COVID-19 hengitystieinfektio | Covid-19-pandemia | COVID-19 akuutti hengitysvaikeusoireyhtymä | COVID-19:ään liittyvä keuhkokuume | COVID 19:ään liittyvä koagulopatia | COVID-19 (koronavirustauti 2019) | COVID-19:ään liittyvä tromboemboliaKreikka
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital ja muut yhteistyökumppanitRekrytointiCOVID-19 | COVID-19 jälkeinen oireyhtymä | Postakuutti COVID-19 | Akuutti COVID-19Kiina
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkEi vielä rekrytointiaCOVIDin jälkeisen taudin hoito hyperbarisella happiterapialla: satunnaistettu, kontrolloitu tutkimusCOVID-19 jälkeinen oireyhtymä | Pitkä COVID | Pitkä Covid19 | COVID-19 jälkeinen tila | COVID-jälkeinen oireyhtymä | COVID-19 jälkeinen tila, määrittelemätön | COVID-jälkeinen tilaAlankomaat
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyValmisCOVID-19 jälkeinen oireyhtymä | Pitkäaikainen COVID-19-oireyhtymäSaksa
-
Endourage, LLCRekrytointiPitkä COVID | Pitkä Covid19 | Postakuutti COVID-19 | Pitkän matkan COVID | Pitkän matkan COVID-19 | Postakuutti COVID-19-oireyhtymäYhdysvallat
Kliiniset tutkimukset COVID-19
-
AstraZenecaValmisCOVID-19Yhdistynyt kuningaskunta
-
Melike CengizValmis
-
Hasanuddin UniversityChulalongkorn UniversityValmis
-
Raphael SerreauAssistance Publique - Hôpitaux de Paris; University Hospital, Paris; François...ValmisKoronavirustartuntaRanska
-
University of PennsylvaniaPublic Health Management CorporationValmis
-
University of PennsylvaniaPublic Health Management CorporationValmis
-
AstraZenecaValmisCovid-19Yhdistynyt kuningaskunta
-
University of Texas at AustinTuntematon
-
Istituto Ortopedico GaleazziTuntematonCovid19 | Reisiluun murtuma | Hauraus murtumaItalia
-
University of AberdeenEi vielä rekrytointiaCovid19 | Keuhkoveritulppa